Using the micromethod of Farmer and Abt, plasma vitamin C content of 9S boys and girls in a middle school was determined throughout the year 1954 to 1955. A dietary survey was also carried out every month of the year, for calculating the vitamin intake. The results of the present study are as follow:1. When the diet contains ample amount of fresh leafy vegetables in season, a satisfactory plasma vitamin C level can be maintained. When the diet is limited in fresh vegetables, plasma vitamin C readily decreases in those seasons.2. There is a significant seasonal variation of plasma vitamin C content Highest values are obtained in winter, the maximal content occurring in December. The minimal value is observed in June. This corresponds to the variation in the. level of vitamin C intake in different seasons. There is no significant difference between Autumn and Winter.3. No definite correlation between plasma vitamin C content and the condition of the gums was observed in the present study.4. The plasma vitamin C content of Chinese and English school children observed by some other authors was lower than that obtained in the present investigation. It is believed that the increase plasma vitamin C of the subjects in this study is mainly due to improvement of the living condition of the population and widespread education of the people in the fundamentals of nutritional science in recent years.

Objective To discuss the preoperative interstitial chemotherapy effect and significance on Ki‐67 and Caspase‐3 in oral squamous cell carcinoma .Methods 60 cases of well‐differentiated oral squamous cell carcinoma were divided into three groups ,non chemotherapy before operation group(n= 30) ,intravenous chemotherapy before operation group (n= 15) and interstitial chemo‐therapy before operation group(n=15) .The expressions of Ki‐67 and Caspase‐3 were determined by immunohistochemical method , then compared between three groups .Results The labelling index of Ki‐67 in tissue of carcinoma were significant differences a‐mong each groups(P< 0 .05) .The labelling index of Ki‐67 in adjacent mucosas of carcinoma were significant differences among three groups(P<0 .05) .The expression rates of Caspase‐3 were significant differences among three groups(P<0 .05) .Conclusion Preoperative interstitial chemotherapy than preoperative intravonous chemotherapy for oral squamous carcinoma more inhibit tumor growth and reduce local recurrence through the inhibition of cell proliferation and induction of cell apoptosis ,thus inhibiting tumor growth .

0.02 0.02

Objective:To evaluate the efficacy of first-line tyrosine kinase inhibitors (TKI) plus immune checkpoint inhibitors (ICI) in metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC).Methods:The data of 87 metastatic FH-deficient RCC patients from West China Hospital ( n=44), Renji Hospital ( n=27) and Sun Yat-sen University Cancer Center (n=16) from Mar 2019 to Aug 2022 were retrospectively analyzed. The median age was 37(30, 47) years, the male to female ratio was 1.9∶1. The median size of tumor was 7.5(5.0, 10.0) cm. Sixty-one patients (70.1%) had germline FH mutations, and 26 patients (29.9%) had somatic FH mutations. Forty-nine patients (56.3%) metastasis disease at initial diagnosis, and 38 patients (43.7%) had metachronous metastasis. The most common site of metastasis was lymph node (41/87, 47.1%), followed by bone (33/87, 37.9%), liver (22/87, 25.3%), and lung (14/87, 16.1%). Fifteen patients (17.2%) had weak expression of FH protein and 59 patients (67.8%) had positive PD-L1 expression. The most common treatments were sintilimab plus axitinib (52/87, 59.8%), followed by pembrolizumab plus cabozantinib (7/87, 8.0%), tirelizumab plus axitinib (6/87, 6.9%), pembrolizumab plus axitinib (5/87, 5.7%), and toripalimab plus axitinib (4/87, 4.6%). Thirteen patients (13/87, 14.9%) received other ICI plus TKI combination treatments. Statistical analysis was conducted using R 4.2.3 software. Kaplan Meier survival curve was used to evaluate survival data, and log-rank test was used to compare differences between treatment groups. Results:The overall objective response rate (ORR) and disease control rate (DCR) of first-line TKI + ICI were 39.1% and 89.7%, respectively. The median progression-free survival (PFS) and overall survival (OS) were 16.5 months and 71.0 months, respectively. For first-line sintilimab plus axitinib, the ORR and DCR were 44.2% and 92.3%, respectively. The median PFS was 17.3 months and the median OS was not reached for this combination treatment. The efficacy of first-line tirelizumab plus axitinib was inferior to other treatment strategies (median PFS: 4.0 vs. 16.6 months, P<0.001; median OS: 22.0 vs. 71.0 months, P=0.043). Subgroup analyses further showed that the efficacy of ICI+ TKI combination therapy was consistent in patients with different clinicopathologic and genomic features. However, patients with liver metastasis had shorter OS than those without liver metastasis (median OS: 26.3 vs. 71.0 months, P=0.021). Conclusion:First-line TKI + ICI is effective for metastatic FH-deficient RCC and can significantly prolong the survival of the patients.